Related Experiment Video

Updated: Feb 1, 2026

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
09:36

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA

Published on: April 10, 2018

26.3K

Long non-coding RNA LOC285194 functions as a tumor suppressor by targeting p53 in non-small cell lung cancer

Huaping Zhou1, Allen Chen2, Jianfei Shen3

  • 1Southern Medical University, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.

Oncology Reports
|December 14, 2018
PubMed

Insights

LOC285194 functions as a tumor suppressor in non-small cell lung cancer (NSCLC). Lower LOC285194 expression correlates with poor survival and targets p53, suggesting its potential in NSCLC gene therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The tumor-suppressor role of LOC285194 is established in various cancers, but its function in non-small cell lung cancer (NSCLC) is uncharacterized.
  • Understanding the role of non-coding RNAs like LOC285194 is crucial for developing novel cancer therapies.

Purpose of the Study:

  • To investigate the biological function and clinical significance of LOC285194 in non-small cell lung cancer (NSCLC).
  • To explore LOC285194's potential as a prognostic indicator and therapeutic target in NSCLC.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) to measure LOC285194 expression in NSCLC tissues.
  • In vitro studies involving gene knockdown and overexpression in lung cancer cell lines (A549, H1299) to assess effects on cell growth, migration, and invasion.
  • RNA pulldown and RNA immunoprecipitation assays to identify direct protein binding partners of LOC285194.

Main Results:

  • LOC285194 expression was significantly downregulated in NSCLC tumor tissues compared to non-tumor tissues (P<0.001) and correlated with tumor size (P=0.027).
  • Reduced LOC285194 expression was associated with worse disease-free and overall survival rates in NSCLC patients (P<0.05).
  • p53 was identified as a direct binding target of LOC285194, and bioinformatics analysis suggested involvement in the KRAS/BRAF/MEK pathway.

Conclusions:

  • LOC285194 acts as a novel non-coding tumor suppressor in NSCLC by targeting p53.
  • Its expression level serves as a prognostic indicator for NSCLC patients.
  • LOC285194 holds potential as a therapeutic target for gene therapy in NSCLC.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

413
Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.0K

Related Concept Videos

Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.6K